C2T2 | Vanderbilt-Ingram Cancer Center

October 25, 2023

VUMC to help engage more study participants in research decisions

Human research will be more equitable, inclusive and stronger if the people who are participants in studies also help plan and guide the direction of those studies.

November 17, 2023

Tumor antigens key to improving cancer immunotherapy study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.

November 17, 2023

Vanderbilts Dr. W. Kimryn Rathmell to be appointed director of the National Cancer Institute

Kimryn Rathmell MD PhD MMHC the Hugh Jackson Professor of Medicine and chair of the Department of Medicine at Vanderbilt University Medical Center will be appointed Director of the National Cancer Institute.

VICC’s Balko named a Susan G. Komen ‘Pink Tie Guy’

Read more about VICC’s Balko named a Susan G. Komen ‘Pink Tie Guy’

Justin Balko, Pharm.D., Ph.

Public invited to learn about VICC precision cancer medicine

Read more about Public invited to learn about VICC precision cancer medicine

Leading cancer investigators from Vanderbilt-Ingram Cancer Center will unveil the latest in cancer research during an upcoming community event. “Precision Medicine in Cancer: At the Crossroads of Research and Treatment for Patients” will be held Tuesday, May 10, from 5:

VICC investigators in spotlight at AACR conference

Read more about VICC investigators in spotlight at AACR conference

A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. Carlos L. Arteaga, M.

Precision medicine already changing cancer treatment strategies

Read more about Precision medicine already changing cancer treatment strategies

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. “Nationwide we’re seeing great promise with this approach […]

V Foundation grants bolster cancer initiatives

Read more about V Foundation grants bolster cancer initiatives

Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC. Raymond Blind, Ph.D.

Arteaga to direct UT Southwestern cancer center

Read more about Arteaga to direct UT Southwestern cancer center

Carlos L. Arteaga, M.D.

Study explores how some breast cancers resist treatment

Read more about Study explores how some breast cancers resist treatment

A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies. The new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators has identified gene alterations […]

Investigators match novel cancer mutations with potential therapies

Read more about Investigators match novel cancer mutations with potential therapies

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […]

Subscribe to C2T2